{
    "nct_id": "NCT01782742",
    "title": "A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2016-02-10",
    "description_brief": "Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and A\u03b2 (harmful protein) production and removal. The study drug \"bexarotene\" is an FDA approved anti-cancer agent but is not approved for use in Alzheimer's disease. Bexarotene acts as an RXR agonist that has reduced A\u03b2 (harmful protein) in the brain in experimental models of Alzheimer's disease.\n\nThis study aims to determine the safety and effect on abnormal proteins found in the brain (based on brain scans) of 300 mg of \"bexarotene\" administered for one month compared to placebo (inactive agent).",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "49 participants were screened, 29 were screen failures, 20 participants were randomized to treatment. 1 was withdrawn after Week 4 treatment. Inclusion and exclusion criteria was the strict basis for eligibility.",
            "recruitmentDetails": "Recruitment was conducted in the United States at one site. The first participant was enrolled in April 2013.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Bexarotene Treatment Arm",
                    "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                },
                {
                    "id": "FG001",
                    "title": "Placebo",
                    "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo"
                }
            ],
            "periods": [
                {
                    "title": "Double-blind Treatment Phase",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "16"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "15"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Open Label Phase",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "19"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "19"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Bexarotene Treatment Arm",
                    "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                },
                {
                    "id": "BG001",
                    "title": "Placebo",
                    "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "16"
                        },
                        {
                            "groupId": "BG001",
                            "value": "4"
                        },
                        {
                            "groupId": "BG002",
                            "value": "20"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Customized",
                    "description": "Age at Screening",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "title": "Age at Screening",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74.9",
                                            "spread": "6.6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "78.1",
                                            "spread": "8.0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "75.5",
                                            "spread": "6.8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "13"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race/Ethnicity, Customized",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Race - Caucasian",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "19"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Race - African American",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Years of Education",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "14.7",
                                            "spread": "4.9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "12.3",
                                            "spread": "3.3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "14.2",
                                            "spread": "4.7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Years of Cognitive Symptoms",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "4.6",
                                            "spread": "1.9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2.8",
                                            "spread": "0.96"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "4.3",
                                            "spread": "1.9"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "MMSE total score",
                    "description": "The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The lowest score that any particular person can get is 0 and the highest score is 30.",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "13.7",
                                            "lowerLimit": "8",
                                            "upperLimit": "23"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "17.0",
                                            "lowerLimit": "11",
                                            "upperLimit": "23"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "14.4",
                                            "lowerLimit": "8",
                                            "upperLimit": "23"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "ADAS-Cog score",
                    "description": "The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 85 (worse). A positive change indicates cognitive worsening.",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "49.9",
                                            "lowerLimit": "35",
                                            "upperLimit": "65"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "40.3",
                                            "lowerLimit": "28",
                                            "upperLimit": "54"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "48.0",
                                            "lowerLimit": "28",
                                            "upperLimit": "65"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "CDR score",
                    "description": "The CDR is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). Higher score means more severe dementia rating. The score is based on interviews with the participant and study partner, using a structured interview that assesses six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1.4",
                                            "lowerLimit": "0",
                                            "upperLimit": "2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1.1",
                                            "lowerLimit": "0",
                                            "upperLimit": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1.4",
                                            "lowerLimit": "0",
                                            "upperLimit": "2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "NPI score",
                    "description": "The NPI is a well validated, reliable, multi-item instrument to assess psychopathology in AD based on interview with the study partner. The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score and the score for each subscale are the product of severity and frequency. Overall score range from 0 meaning no disturbance to 144 meaning severe disturbance.",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8.7",
                                            "lowerLimit": "0",
                                            "upperLimit": "29"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7.0",
                                            "lowerLimit": "2",
                                            "upperLimit": "16"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "8.4",
                                            "lowerLimit": "0",
                                            "upperLimit": "29"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "NPI Distress Score",
                    "description": "NPI distress score measures the distress that the caregiver experiences during the previous 4 weeks from the assessment date. Distress score is measured on a scale between 0 to 5. 0 being not at all distressed to 5 very severely or extremely distressed. The scores for all 12 domains are added up becomes the total score. 0 means no caregiver distress and 60 means extreme caregiver distress.",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6.5",
                                            "lowerLimit": "0",
                                            "upperLimit": "35"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "4.3",
                                            "lowerLimit": "2",
                                            "upperLimit": "6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "6.1",
                                            "lowerLimit": "0",
                                            "upperLimit": "35"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "ADCS-ADL score",
                    "description": "The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Overall score range from 0 meaning fully independent to 78 meaning fully dependent on assistance for activities of daily living.",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "53.7",
                                            "lowerLimit": "34",
                                            "upperLimit": "77"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "64.5",
                                            "lowerLimit": "37",
                                            "upperLimit": "76"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "55.9",
                                            "lowerLimit": "34",
                                            "upperLimit": "77"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "ApoE4 Status",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Non-carriers",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Heterozygotes",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Homozygotes",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain",
                    "description": "The primary study endpoint for all subjects is the change from baseline to Week 4 in amyloid burden as measured by standard uptake units regional (SUVr) on amyloid brain imaging obtained through 18F-AV-45 PET",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "SUVr",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.03",
                                            "lowerLimit": "-0.06",
                                            "upperLimit": "0.01"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.02",
                                            "lowerLimit": "-0.05",
                                            "upperLimit": "0.10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.22",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.05",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.13",
                            "ciUpperLimit": "0.03"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in MMSE Score in ALL Subjects From Baseline to Week 4",
                    "description": "The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The lowest score that any particular person can get is 0 and the highest score is 30.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "points",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.750",
                                            "lowerLimit": "-0.783",
                                            "upperLimit": "2.283"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.750",
                                            "lowerLimit": "-1.316",
                                            "upperLimit": "4.816"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.57",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-1.000",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-4.428",
                            "ciUpperLimit": "2.428"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4",
                    "description": "The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 85 (worse). A positive change indicates cognitive worsening.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "points",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.375",
                                            "lowerLimit": "-2.153",
                                            "upperLimit": "2.903"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.250",
                                            "lowerLimit": "-5.307",
                                            "upperLimit": "4.807"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.83",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.625",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-5.029",
                            "ciUpperLimit": "6.279"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4",
                    "description": "The CDR is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). Higher score means more severe dementia rating. The score is based on interviews with the participant and study partner, using a structured interview that assesses six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.000",
                                            "lowerLimit": "0.000",
                                            "upperLimit": "0.000"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.000",
                                            "lowerLimit": "0.000",
                                            "upperLimit": "0.000"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.000",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.000",
                            "ciUpperLimit": "0.000"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in NPI Scores in ALL Subjects From Baseline to Week 4",
                    "description": "The NPI is a well validated, reliable, multi-item instrument to assess psychopathology in AD based on interview with the study partner. The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score and the score for each subscale are the product of severity and frequency. Overall score range from 0 meaning no disturbance to 144 meaning severe disturbance",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "points",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-2.625",
                                            "lowerLimit": "-6.783",
                                            "upperLimit": "1.533"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-2.250",
                                            "lowerLimit": "-10.570",
                                            "upperLimit": "6.067"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.94",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.375",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-9.674",
                            "ciUpperLimit": "8.924"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4",
                    "description": "The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Overall score range from 0 meaning fully independent to 78 meaning fully dependent on assistance for activities of daily living",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "points",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.938",
                                            "lowerLimit": "-4.861",
                                            "upperLimit": "0.986"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-6.500",
                                            "lowerLimit": "-12.350",
                                            "upperLimit": "-0.653"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.18",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "4.563",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.975",
                            "ciUpperLimit": "11.100"
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Primary Outcome by Genotype (ALL SUBJECTS)",
                    "description": "This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers compared to E-4 non-carriers)",
                    "populationDescription": "Change om composite and regional Beta Amyloid burden according to ApoE genotype on ALL SUBJECTS",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "SUVr",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Frontal Medial Orbital",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.043",
                                            "lowerLimit": "-0.081",
                                            "upperLimit": "-0.006"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.021",
                                            "lowerLimit": "-0.096",
                                            "upperLimit": "0.054"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Anterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.040",
                                            "lowerLimit": "-0.080",
                                            "upperLimit": "0.000"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.018",
                                            "lowerLimit": "-0.061",
                                            "upperLimit": "0.098"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Parietal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.003",
                                            "lowerLimit": "-0.034",
                                            "upperLimit": "0.027"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.044",
                                            "lowerLimit": "-0.018",
                                            "upperLimit": "0.105"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Posterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.017",
                                            "lowerLimit": "-0.065",
                                            "upperLimit": "0.031"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.044",
                                            "lowerLimit": "-0.052",
                                            "upperLimit": "0.141"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Precuneus",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.027",
                                            "lowerLimit": "-0.069",
                                            "upperLimit": "0.014"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.040",
                                            "lowerLimit": "-0.043",
                                            "upperLimit": "0.122"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Temporal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.038",
                                            "lowerLimit": "-0.075",
                                            "upperLimit": "0.000"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.016",
                                            "lowerLimit": "-0.059",
                                            "upperLimit": "0.090"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Primary Outcome by Genotype (NON ApoE4 CARRIERS)",
                    "description": "Measures changes from baseline on treatment compared to placebo at week 4 on composite and regional Beta Amyloid burden according to ApoE genotype (NON ApoE4 CARRIERS)",
                    "populationDescription": "Change in composite and regional Beta Amyloid Burden on non-ApoE4 carriers",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "SUVr",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "4"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "3"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Composite",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.097",
                                            "lowerLimit": "-0.155",
                                            "upperLimit": "-0.040"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.047",
                                            "lowerLimit": "-0.019",
                                            "upperLimit": "0.114"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Frontal Medial Orbital",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.076",
                                            "lowerLimit": "-0.146",
                                            "upperLimit": "-0.007"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.005",
                                            "lowerLimit": "-0.075",
                                            "upperLimit": "0.085"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Anterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.096",
                                            "lowerLimit": "-0.166",
                                            "upperLimit": "-0.026"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.048",
                                            "lowerLimit": "-0.034",
                                            "upperLimit": "0.129"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Parietal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.068",
                                            "lowerLimit": "-0.107",
                                            "upperLimit": "-0.029"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.065",
                                            "lowerLimit": "0.020",
                                            "upperLimit": "0.110"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Posterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.113",
                                            "lowerLimit": "-0.180",
                                            "upperLimit": "-0.046"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.074",
                                            "lowerLimit": "-0.004",
                                            "upperLimit": "0.151"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Precuneus",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.127",
                                            "lowerLimit": "-0.188",
                                            "upperLimit": "-0.066"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.062",
                                            "lowerLimit": "-0.008",
                                            "upperLimit": "0.132"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Temporal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.104",
                                            "lowerLimit": "-0.162",
                                            "upperLimit": "-0.045"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.031",
                                            "lowerLimit": "-0.037",
                                            "upperLimit": "0.098"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Primary Outcome by Genotype (ApoE4 CARRIERS)",
                    "description": "This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers)",
                    "populationDescription": "Change in composite and regional Beta Amyloid burden on ApoE4 carriers",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "SUVr",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "12"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "1"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Composite",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.005",
                                            "lowerLimit": "-0.041",
                                            "upperLimit": "0.031"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.048",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Frontal Medial Orbital",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.033",
                                            "lowerLimit": "-0.074",
                                            "upperLimit": "0.009"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.099",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Anterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.022",
                                            "lowerLimit": "-0.062",
                                            "upperLimit": "0.019"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.069",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Parietal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.018",
                                            "lowerLimit": "-0.013",
                                            "upperLimit": "0.050"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.019",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Posterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.015",
                                            "lowerLimit": "-0.035",
                                            "upperLimit": "0.065"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.044",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Precuneus",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.006",
                                            "lowerLimit": "-0.031",
                                            "upperLimit": "0.043"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.027",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Temporal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.015",
                                            "lowerLimit": "-0.055",
                                            "upperLimit": "0.024"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.030",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)",
                    "description": "This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HETEROZYGOTE ApoE4 CARRIERS)",
                    "populationDescription": "Change in composite and regional Beta Amyloid burden on Heterozygote ApoE4 carriers",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "SUVr",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "6"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "1"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Composite",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.015",
                                            "lowerLimit": "-0.037",
                                            "upperLimit": "0.008"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.048",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Frontal Medial Orbital",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.061",
                                            "lowerLimit": "-0.090",
                                            "upperLimit": "-0.033"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.099",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Anterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.048",
                                            "lowerLimit": "-0.080",
                                            "upperLimit": "-0.016"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.069",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Parietal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.034",
                                            "lowerLimit": "0.009",
                                            "upperLimit": "0.058"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.019",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Posterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.007",
                                            "lowerLimit": "-0.035",
                                            "upperLimit": "0.022"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.044",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Precuneus",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.005",
                                            "lowerLimit": "-0.021",
                                            "upperLimit": "0.032"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.027",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Temporal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.010",
                                            "lowerLimit": "-0.041",
                                            "upperLimit": "0.020"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.030",
                                            "lowerLimit": "NA",
                                            "upperLimit": "NA",
                                            "comment": "With 1 placebo patient, variability within the group cannot measured effectively"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)",
                    "description": "This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HOMOZYGOTE ApoE4 CARRIERS)\n\nThere are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm.",
                    "populationDescription": "Change in composite and regional Beta Amyloid burden on Homozygote ApoE4 carriers.\n\nThere are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "SUVr",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "6"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Composite",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.005",
                                            "lowerLimit": "-0.066",
                                            "upperLimit": "0.075"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Frontal Medial Orbital",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.004",
                                            "lowerLimit": "-0.077",
                                            "upperLimit": "0.069"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Anterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.005",
                                            "lowerLimit": "-0.067",
                                            "upperLimit": "0.077"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Parietal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.003",
                                            "lowerLimit": "-0.054",
                                            "upperLimit": "0.060"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Posterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.037",
                                            "lowerLimit": "-0.059",
                                            "upperLimit": "0.133"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Precuneus",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.006",
                                            "lowerLimit": "-0.065",
                                            "upperLimit": "0.077"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Temporal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.020",
                                            "lowerLimit": "-0.096",
                                            "upperLimit": "0.055"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)",
                    "description": "Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes",
                    "populationDescription": "Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes in ALL SUBJECTS. There were only a total of 17 subjects who were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 3 subjects were unsuccessful.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "pmol/L",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Beta Amyloid 40",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.186",
                                            "lowerLimit": "-3.673",
                                            "upperLimit": "18.045"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-5.330",
                                            "lowerLimit": "-24.910",
                                            "upperLimit": "14.246"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Beta Amyloid 42",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.585",
                                            "lowerLimit": "-0.044",
                                            "upperLimit": "1.213"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.900",
                                            "lowerLimit": "-2.033",
                                            "upperLimit": "0.233"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)",
                    "description": "Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes (non ApoE4 carriers)",
                    "populationDescription": "Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels in non ApoE4 carriers. Of the 7 total subjects who were non-ApoE carriers, only 6 subjects were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 1 subject were unsuccessful.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "pmol/L",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "3"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "3"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Beta Amyloid 40",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-3.503",
                                            "lowerLimit": "-22.840",
                                            "upperLimit": "15.836"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-8.550",
                                            "lowerLimit": "-27.890",
                                            "upperLimit": "10.789"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Beta Amyloid 42",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.293",
                                            "lowerLimit": "-0.873",
                                            "upperLimit": "1.460"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.127",
                                            "lowerLimit": "-2.293",
                                            "upperLimit": "0.040"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects",
                    "description": "This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in all subjects",
                    "populationDescription": "There were only a total of 17 subjects who were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 3 subjects were unsuccessful.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "ratio",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "4"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.001",
                                            "lowerLimit": "-0.007",
                                            "upperLimit": "0.008"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.005",
                                            "lowerLimit": "-0.019",
                                            "upperLimit": "0.009"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.46",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.006",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.010",
                            "ciUpperLimit": "0.021"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers",
                    "description": "This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in non ApoE4 Carriers",
                    "populationDescription": "Of the 7 total subjects who were non-ApoE carriers, only 6 subjects were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 1 subject were unsuccessful.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "ratio",
                    "timeFrame": "Baseline to Week 4",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bexarotene",
                            "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "3"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "3"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.005",
                                            "lowerLimit": "-0.016",
                                            "upperLimit": "0.026"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.005",
                                            "lowerLimit": "-0.026",
                                            "upperLimit": "0.017"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.53",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.010",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.020",
                            "ciUpperLimit": "0.040"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "Adverse events data were collected from the time the participants signed the informed consent forms to the Post-Treatment Follow Up Visit approximating to 4 months of time when adverse events were captured",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Bexarotene Treatment Arm",
                    "description": "75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nBexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 16,
                    "otherNumAffected": 14,
                    "otherNumAtRisk": 16
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.\n\nWeeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)\n\nPlacebo",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 4,
                    "otherNumAffected": 0,
                    "otherNumAtRisk": 4
                }
            ],
            "otherEvents": [
                {
                    "term": "Dry cough",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 4
                        }
                    ]
                },
                {
                    "term": "Blister on toe",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Participant had a blister on 2nd toe of left foot",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 4
                        }
                    ]
                },
                {
                    "term": "Elevated triglyceride levels",
                    "organSystem": "Hepatobiliary disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 13,
                            "numAffected": 13,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 4
                        }
                    ]
                },
                {
                    "term": "Elevated cholesterol level",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 4
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "limitationsAndCaveats": {
                "description": "Sample size of this trial is small. There was 1 participant withdrawal due to adverse event. Primary outcome measures were completed by all 20 participants as anticipated."
            },
            "certainAgreement": {
                "piSponsorEmployee": true
            },
            "pointOfContact": {
                "title": "Jeffrey Cummings, MD, ScD",
                "organization": "Cleveland Clinic Lou Ruvo Center for Brain Health",
                "email": "cumminj@ccf.org",
                "phone": "702.483.6029"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "bexarotene (RXR agonist)"
    ],
    "placebo": [
        "placebo (inactive agent)"
    ],
    "explanation_target": [
        "Reason: Bexarotene is an oral retinoid X receptor (RXR) agonist \u2014 a small-molecule 'rexinoid' \u2014 that has been shown to reduce brain A\u03b2 and stimulate A\u03b2 clearance in AD mouse models. \ue200cite\ue202turn0search1\ue202turn0search4\ue201.",
        "Act: The described trial (BEAT-AD) randomized patients to 300 mg bexarotene vs placebo for 4 weeks and used amyloid imaging and A\u03b2 biomarkers as primary/biomarker outcomes; the intervention aims to change Alzheimer\u2019s pathology (A\u03b2). This matches a disease-modifying/pathology-targeted mechanism rather than a pure symptomatic cognitive enhancer or neuropsychiatric treatment. \ue200cite\ue202turn0search8\ue202turn0search5\ue201.",
        "Support: Bexarotene is FDA-approved for oncology (cutaneous T-cell lymphoma, brand Targretin) and is being repurposed here; mechanistic and preclinical AD rationale and the human proof-of-concept trial are documented. \ue200cite\ue202turn0search9\ue202turn0search1\ue201.",
        "Reflect: Classification as a 'disease-targeted small molecule' fits because (1) the drug is a small-molecule RXR agonist (not a biologic), (2) its intended effect in the trial is to lower/alter A\u03b2 pathology (disease-targeted), and (3) the trial\u2019s primary measures are pathology biomarkers (amyloid imaging, serum/CSF A\u03b2). Note: the trial was short and biomarker-focused; clinical benefit was not consistently demonstrated and safety (e.g., elevated triglycerides) was observed \u2014 bexarotene remains unapproved for AD and should be considered investigational in this context. \ue200cite\ue202turn0search8\ue202turn0search0\ue201.",
        "Key web sources consulted: PubMed/PMC BEAT-AD trial (randomized 300 mg \u00d74 weeks, amyloid imaging primary outcome). \ue200cite\ue202turn0search8\ue202turn0search0\ue201",
        "Preclinical RXR/bexarotene mouse study showing rapid A\u03b2 reduction and cognitive improvement. \ue200cite\ue202turn0search1\ue201",
        "NCI / drug info showing bexarotene (Targretin) is FDA-approved for cancer (repurposing context). \ue200cite\ue202turn0search9\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug (bexarotene) is an RXR (retinoid X receptor) agonist being tested with the explicit goal of reducing brain A\u03b2 and stimulating A\u03b2 clearance; the clinical trial used amyloid imaging and A\u03b2 biomarkers as primary/biomarker outcomes, indicating a pathology-directed (amyloid) mechanism rather than a purely symptomatic target. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Act: Extracted details from the trial description and literature \u2014 drug: bexarotene (RXR agonist); trial (BEAT\u2011AD) randomized patients to 300 mg bexarotene vs placebo for 4 weeks with amyloid imaging as the primary outcome; mechanism described is stimulation of ApoE-dependent A\u03b2 clearance via RXR/LXR pathways. Based on these facts, the most specific CADRO category is A) Amyloid beta. \ue200cite\ue202turn0search0\ue202turn0search5\ue202turn0search6\ue201",
        "Reflect: Confirmation and caveats \u2014 classification as A) Amyloid beta fits because the trial\u2019s stated intent and primary outcome focus on altering A\u03b2 pathology. Note the mechanism also involves ApoE/lipid-related pathways (RXR\u2192LXR\u2192ApoE/ABCA1), which is related to CADRO category C (ApoE, Lipids and Lipoprotein Receptors); however, the trial\u2019s primary pathological target and biomarker endpoints are A\u03b2, so A) Amyloid beta is the best single-category assignment. Also acknowledge that preclinical and clinical findings have been mixed (replication concerns and safety signals), which does not change the primary amyloid-directed intent. \ue200cite\ue202turn0search5\ue202turn0search6\ue202turn0search2\ue201",
        "Supporting web search results (key sources consulted): (1) BEAT\u2011AD proof\u2011of\u2011concept randomized trial (300 mg \u00d7 4 weeks; amyloid imaging primary outcome). \ue200cite\ue202turn0search0\ue201 (2) Cramer et al., Science 2012 \u2014 preclinical report that bexarotene (RXR agonist) rapidly reduced A\u03b2 and improved function in AD mouse models. \ue200cite\ue202turn0search5\ue201 (3) Follow-up/replication and commentary showing mixed replication of the original preclinical effects. \ue200cite\ue202turn0search2\ue202turn0search3\ue201 (4) Drug information and approval context for bexarotene (Targretin) in oncology (CTCL) from NCI / product information. \ue200cite\ue202turn0search4\ue202turn0search8\ue201"
    ]
}